top of page

Evusheld Available Now

Updated: Mar 24, 2022

Call to schedule a consult (828) 761-1710

LifeWay Health is now able to provide Evusheld to patients 12 and older. Evusheld is the only monoclonal antibody developed to provide prophylactic protection from COVID-19.

Evusheld is administered in two intramuscular injections. Below is the eligibility for administration. This may provide 6-12 months of protection from COVID-19.

Evusheld Eligibility Criteria:

Adults and pediatric individuals (12 years of age and older weighing at least 88 pounds 40 kg):

  • Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2, AND:

    • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, OR

    • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

Moderate to severe immune compromise includes:

  • Receiving active chemotherapy for any solid tumor malignancy

  • Hematological malignancy

  • Solid organ transplant and are taking immunosuppressants

  • Receipt of CAR-T within 2 years or maintained on immunosuppression

  • Hematopoietic cell transplant within past 2 years or maintained on immunosuppression or IgG replacement

  • Primary immunodeficiency

  • AIDS (CD4 < 200 or 15%)

  • GVHD receiving immunosuppression

  • Receiving T- or B- cell compromising drug

  • Anatomic or functional asplenia

  • Sickle cell anemia or thalassemia

  • Aplastic anemia

  • Stage IV CKD or worse (i.e., requiring renal replacement therapy)

  • Neutropenia (ANC < 1000)

  • Myelodysplastic syndrome on therapy

  • Age ≥65 AND

    • Nonresponsive antibody assay OR

    • 2 or more impairments of Assisted Daily Living (ADL)

  • SARS-CoV-2 antibody seronegative after 3 previous vaccines*

  • All other immunosuppressive conditions receiving immunotherapy**

27 views0 comments

Recent Posts

See All


bottom of page